How Long Does a GLP-1 Take to Work? A Realistic Timeline

A GLP-1 usually takes months, not weeks, to show its full effect. The first month is a low starting dose meant to let your body adjust, and on the FDA-approved schedules it takes about four to five months of step-ups to reach the higher maintenance doses. The trials behind those products measured their headline results after more than a year.

At Padgett Medical Center in Tampa, personalized compounded semaglutide starts at $149 a month and personalized compounded tirzepatide at $229 a month at the starting dose. New patients who book online with a card on file take 15% off their first month of medication, and the $100 visit is free when you start medication. Nothing is charged when you book. See every program and price.

Why does the first month use such a low dose?

Starting doses are chosen for tolerability, not maximum effect. Raising the dose in steps gives your stomach time to adjust and lowers the risk of nausea, vomiting and diarrhea.

The FDA-approved labels say so directly. Tirzepatide's prescribing information starts at 2.5 mg once weekly for 4 weeks and states that the 2.5 mg dose 'is for treatment initiation and is not approved as a maintenance dosage.' The dose then rises in 2.5 mg steps, at least 4 weeks apart, to a maintenance dose of 5, 10 or 15 mg. Semaglutide's prescribing information starts at 0.25 mg for weeks 1 to 4, then steps to 0.5 mg, 1 mg and 1.7 mg, reaching a maintenance dose of 1.7 mg or 2.4 mg (recommended) from week 17. Both labels describe the step-ups as a way to reduce the risk of stomach side effects.

The timeline can stretch. If a step-up is hard to tolerate, the semaglutide label says to consider delaying the next increase by 4 weeks. At Padgett, your dose starts low and your provider raises it at follow-up visits based on how you respond and how you feel, so the pace is set for you. Never change your dose on your own.

What did the trials of FDA-approved GLP-1s show over time?

They showed large average losses that built over more than a year, in people who were also following a reduced-calorie diet and activity plan. These were trials of FDA-approved products, not of Padgett's compounded medications, and averages don't predict any one person's result.

Semaglutide: in the STEP 1 trial, adults without diabetes taking 2.4 mg weekly lost an average of 14.9% of their body weight by week 68, compared with 2.4% on placebo. In a separate trial, STEP 4, people who completed a 20-week start-up period (16 weeks of step-ups, then 4 weeks at 2.4 mg) had lost 10.6% on average by week 20.

Tirzepatide: in the main trial summarized in its prescribing information, adults without diabetes lost an average of 15.0%, 19.5% and 20.9% of their weight at 5, 10 and 15 mg after 72 weeks, compared with 3.1% on placebo. Those 72 weeks included at least 52 weeks at the maintenance dose, and everyone had counseling on a reduced-calorie diet and at least 150 minutes a week of activity.

Not everyone responds the same way. In STEP 1, 86.4% of people on semaglutide lost at least 5% of their weight by week 68, which also means about 1 in 7 did not.

What's realistic in the first month?

Expect modest changes. You're on the starting dose, and these medications work mainly by lowering how much you eat: both labels say they decrease calorie intake, likely by affecting appetite. So watch your appetite and portions, not only the scale.

Early numbers vary widely, and a slow start is not a verdict. A later analysis of the SURMOUNT-1 trial of FDA-approved tirzepatide looked at week 8, after 4 weeks at the starting dose and 4 at the next. About 6 in 10 participants had already lost at least 5%, averaging about 8%. The other 4 in 10 had lost about 3%. By week 72, that slower group averaged about 15%: less than the fast starters' 23%, but still a large loss.

Weigh yourself once a week, on the same scale at the same time of day, and write it down. Daily readings bounce around; a weekly trend across a month tells you far more.

What changes between months 3 and 6?

Months 3 to 6 are usually when the dose reaches a maintenance level and weight loss becomes easier to see. On the FDA-approved schedules, semaglutide reaches its maintenance dose at week 17, and tirzepatide reaches its highest dose at week 21 at the earliest.

This is also when your provider can judge whether the medication is working for you. NIDDK says that if you don't lose at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will probably advise stopping that medication and may change your plan or try a different one. Note the words 'on the full dose': that clock starts after the step-ups, not on day one.

A useful yardstick: NIDDK notes that losing 5% to 10% of your starting weight may improve blood sugar, blood pressure and triglycerides. For someone who weighs 220 pounds, that's 11 to 22 pounds.

What are the signs it's working besides the scale?

Look at your appetite, your waist, how your clothes fit, your blood pressure, your lab results and how easily you move. In trials of FDA-approved products, these measures improved along with weight.

STEP 1 reported greater improvements in heart and metabolic risk factors, and in participant-reported physical functioning, with semaglutide than with placebo. In the SURMOUNT-1 analysis above, even the slower early group averaged a waist reduction of about 14 cm, roughly 5 inches, by week 72, along with lower blood pressure. NIDDK adds that losing weight can also improve problems such as joint pain and sleep apnea.

To track these, measure your waist once a month at the same spot, note when clothes loosen, keep home blood pressure readings if you have a cuff, and ask your provider about repeat labs. Write the changes down; they're easy to forget by your next visit.

When should you talk to your provider about slow progress?

Bring it up at your monthly follow-up, with your weekly weights and notes, rather than changing anything yourself. Call sooner if side effects keep you from eating or drinking normally.

A slow first month on a starting dose is expected. What's worth discussing is a trend: several weeks without change at a higher dose, side effects that keep your dose from going up, or old eating patterns creeping back. Your provider can look at the dose, the pace and your habits together. For habits that help, read lifestyle habits that support GLP-1 treatment; for side effects, see GLP-1 side effects: what helps.

How does Padgett track your progress?

Follow-ups at Padgett are monthly with Morgan Colee, PA, in person at our Tampa clinic or by telehealth anywhere in Florida. Each one reviews your weight trend, appetite, side effects and how you feel, then keeps or adjusts your dose.

No amount of weight loss is promised. Your plan is built around your starting point and the pace your body tolerates. For telehealth, you need to be in Florida at the time of the visit and show a valid Florida driver's license or state ID on camera. Book your visit.

Personalized compounded semaglutide and personalized compounded tirzepatide are compounded drugs that have not been approved by the FDA. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved products containing semaglutide and tirzepatide are available. Individual results vary.

This article is educational and is not medical advice. Talk with a licensed provider about your own health, medications and treatment options.